Lantern Pharma CEO Advocates AI-Driven Transformation of 'Broken' Biotech Model at BioNTX Summit

Lantern Pharma CEO Panna Sharma participated as both moderator and panelist at the 2025 BioNTX iC3 Summit, where biotechnology leaders declared the traditional drug development model broken. Sharma emphasized that the process of making drugs remains largely manual despite available technology that could transform the industry. The Dallas-based clinical-stage biopharmaceutical company leverages its RADR AI platform to address these inefficiencies in oncology drug development.

Sharma was quoted stating that the industry has not adopted transformative technology fast enough to overcome longstanding challenges. AI-driven platforms like RADR can streamline discovery processes, accelerate clinical timelines, and significantly reduce costs according to the summit discussion. This approach directly responds to the event's call for innovation and efficiency in biopharmaceutical development. The full coverage of the summit can be viewed at https://ibn.fm/DM9ur.

By advancing a data-driven model, Lantern Pharma positions itself at the forefront of efforts to create a more sustainable future for biotechnology. The company's proprietary AI and machine learning platform utilizes over 200 billion oncology-focused data points and more than 200 advanced ML algorithms. This technological foundation helps address significant challenges in oncology drug development that have traditionally required extensive time and financial resources.

The RADR platform represents a shift toward computational approaches that could revolutionize how cancer treatments are discovered and developed. Lantern Pharma's growing pipeline of therapies spans multiple cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company's development programs include Phase 2 clinical programs and multiple Phase 1 clinical trials, demonstrating the practical application of their AI-driven methodology.

Industry leaders at the summit highlighted the urgent need for transformation in biopharmaceutical development processes. The traditional model's inefficiencies have contributed to escalating costs and extended timelines for bringing new treatments to market. AI platforms offer the potential to analyze vast datasets, identify promising drug candidates more efficiently, and optimize clinical trial designs. This technological evolution could ultimately make life-changing therapies more accessible to cancer patients worldwide.

Lantern Pharma's approach exemplifies how artificial intelligence is reshaping oncology research and development. The company estimates its AI-driven pipeline of innovative product candidates has a combined annual market potential exceeding $15 billion USD. As the biotech industry confronts the limitations of conventional methods, AI-driven solutions like those championed by Lantern Pharma may define the future of drug discovery and development.